<DOC>
	<DOCNO>NCT02128126</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability HPV-specific immune response different dos ISA101 vaccine without pegylated IFNα combination therapy carboplatin paclitaxel . To qualitatively assess safety profile HPV-specific immune response ISA101b vaccine compare ISA101 dose level . To assess safety HPV-specific immune response ISA101b vaccine carboplatin , paclitaxel without bevacizumab .</brief_summary>
	<brief_title>Study Therapeutic Vaccine ( ISA101/ISA101b ) Treat Advanced Recurrent Cervical Cancer</brief_title>
	<detailed_description>A majority cervical carcinoma cause uncontrolled , persistent infection high risk Human Papilloma Virus ( HPV ) . ISA101/ISA101b novel therapeutic synthetic long peptide ( SLP ) vaccine target HPV16 develop show efficacy patient high-grade premalignant vulvar lesion cause HPV minor toxicity . For advanced cancer , chemotherapy remain treatment modality choice consider immunosuppressive . However , accumulate evidence indicate many modality conventional chemotherapy less immunosuppressive previously think fact exert favorable effect tumor micro-environment interfering suppressive immune cell stimulate release immune activate molecule tumor cell . Thus chemotherapy may enhance tumor-specific immunity synergize cancer immunotherapy . Addition pegylated interferon alpha ( IFNα ) two-b ( IIb ) vaccination might even improve immune response . This multicenter , open label , non-randomized Phase I/II study perform assess safety tolerability ISA101/ISA101b vaccine , immune modulating effect ISA101 ( without pegylated IFNα ) /ISA101b combine carboplatin paclitaxel , without bevacizumab .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Women ≥ 18 year age . 2 . Cervical cancer confirm histology . 3 . Advanced metastatic recurrent cervical cancer confirm clinical and/or radiological proof curative treatment option . 4 . For cohort 10 ( 12 ) , i.e . patient eligible receive bevacizumab site per standard care , patient may primary stage IVB ( include persistent ) first recurrent carcinoma uterine cervix ( squamous cell carcinoma , adenocarcinoma , adenosquamous carcinoma ) . Prior treatment chemotherapy recurrent disease permit . However , one prior line chemotherapy platinum primary radiochemotherapy platinumbase chemotherapy neoadjuvant chemotherapy prior surgery permit 5 . Tumour must HPV16 positive . 6 . Patients eligible chemotherapy carboplatin paclitaxel , consent chemotherapy carboplatin paclitaxel , start inform consent procedure study . 7 . Performance status ( WHO scale/ECOG ) 1 . 8 . Written inform consent accord local guideline . 9 . Written approval treat physician/investigator his/her clinical judgment patient reasonable life expectancy sufficiently fit motivate complete study treatment comply study procedure conform protocol . Treatment : 1 . Prior treatment antiHPV agent . 2 . Chronic systemic steroid use . Local application ( i.e . stable dos topical inhaled corticosteroid ) allow . 3 . Less 4 week since last treatment cancer therapy , ( i.e . endocrine therapy , immunotherapy , radiotherapy , chemotherapy , etc ) , less 8 week cranial radiotherapy , less 6 week nitrosoureas mitomycin C. 4 . Toxicities result previous anticancer therapy must resolve ≤ grade 2 . 5 . Recent treatment ( within 30 day first study treatment ) another investigational drug . 6 . Patients know hypersensitivity component Investigational Medicinal Product . 7 . Any contraindication use authorize applied product ( i.e . paclitaxel , carboplatin bevacizumab ) . Haematology biochemistry : 8 . Inadequate bone marrow function : Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L , platelet count &lt; 100 x 109/L hemoglobin &lt; 6 mmol/L . 9 . Inadequate liver function , define : Serum ( total ) bilirubin &gt; 2 x upper normal limit ( ULN ) ; Aspartate Aminotransferase ( ASAT ) Alanine Aminotransferase ( ALAT ) &gt; 2.5 x ULN ( &gt; 5 x ULN patient liver metastasis ) ; Alkaline phosphatase level &gt; 2.5 x ULN ( &gt; 5 x ULN patient liver metastasis , &gt; 10 x ULN patient bone metastasis ) . Other : 10 . Clinical suspicion radiological evidence brain leptomeningeal metastasis . 11 . Previous current malignancy site , exception basal squamous cell carcinoma skin exception malignancy patient may consider cure evidenced complete regression lesion &gt; 10 year ago . 12 . Active HIV , chronic hepatitis B C infection . 13 . Patients childbearing potential willing consistently correctly u contraceptive method accord ICH ( M3 ) result low failure rate , i.e . le 1 % per year oral contraceptive use effective mean contraception . 14 . Pregnancy lactation . Serum pregnancy test perform within 7 day prior study treatment start patient childbearing potential . 15 . Major surgical procedure within 28 day prior first study treatment . 16 . Uncontrolled sustained hypertension ( systolic &gt; 180 mm Hg and/or diastolic &gt; 110mm Hg ) . 17 . Clinically significant ( i.e . active ) cardiovascular disease define : Stroke within ≤ 6 month prior day 1 ; Transient Ischemic Attack ( TIA ) within ≤ 6 month prior day 1 ; Myocardial infarction within ≤ 6 month prior day 1 ; Unstable angina ; New York Heart Association ( NYHA ) Grade II great Congestive Heart Failure ( CHF ) ; Serious cardiac arrhythmia require medication ; 18 . History severe bronchial asthma and/or severe allergy . 19 . Evidence medical condition may interfere plan treatment , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Advanced recurrent cervical cancer</keyword>
	<keyword>HPV16 positive</keyword>
	<keyword>No curative treatment option</keyword>
</DOC>